Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Biosciences to Sell $20M in Preferred Stock, Plans Reverse Stock Split

NEW YORK — Interpace Biosciences said on Monday that it has signed an agreement to sell $20 million in Series B preferred stock and that it is planning a one-for-10 reverse stock split.

According to the Parsippany, New Jersey-based company, 1315 Capital will purchase $19 million worth of the preferred stock, with the remaining $1 million being sold to existing investor Ampersand Capital Partners. The preferred stock is convertible into common stock at a conversion price of $.60 per share prior to the planned reverse stock split.

Ampersand has also agreed to exchange its existing $27 million of Series A preferred stock, which has a conversion price of $.80 per share, for newly issued Series B preferred stock in consideration of eliminating all past and future accrued dividends and all anti-dilution price adjustments, Interpace said. The Series B preferred stock will not accrue dividends or have anti-dilution price adjustments.

The planned reverse stock split, which is intended to boost Interpace's share price in order to meet the Nasdaq's minimum bid price requirement for continued listing will take place upon closing of the Series B preferred stock sale and is expected to be effective within one week, Interpace noted.

During early morning trading, Interpace shares were up around 2 percent at $.6611.

"We believe this proposed change in capital structure can benefit our stockholders and make our stock more attractive to institutional and other investors," Interpace President and CEO Jack Stover said in a statement.

The company recently changed its name from Interpace Diagnostics as it expands its focus beyond diagnostics to include drug discovery and development services in cancer and, potentially, other disease areas. It said the Series B preferred stock sale will help it achieve cash flow break even and accelerate its growth and acquisition strategy.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.